Cencora, Inc.

Cencora, Inc., a pharmaceutical preparation manufacturing company headquartered in the US, has reported its greenhouse gas (GHG) emissions and climate commitments.

For the fiscal year 2025, Cencora reported total emissions of approximately 46.5 billion kg CO2e. This total comprises Scope 1 emissions of about 190 million kg CO2e, Scope 2 (market-based) emissions of approximately 80 million kg CO2e, and significant Scope 3 emissions totalling about 46.1 billion kg CO2e.

In fiscal year 2024, Cencora's total emissions were approximately 40.7 billion kg CO2e. This included Scope 1 emissions of about 135 million kg CO2e, Scope 2 (market-based) emissions of approximately 79 million kg CO2e, and Scope 3 emissions amounting to roughly 40.5 billion kg CO2e. The company's Scope 3 emissions in this year were predominantly driven by purchased goods and services, estimated at over 39.4 billion kg CO2e.

The company has established ambitious climate targets. Cencora commits to reducing absolute Scope 1 and Scope 2 GHG emissions by 54.6% by fiscal year 2032, using fiscal year 2019 as the base year. This target is recognised as being consistent with the reductions required to limit global warming to 1.5°C. Furthermore, Cencora aims for 82% of its suppliers, measured by spend in purchased goods and services, to have science-based targets by fiscal year 2027. Cencora also has a long-term aspiration to achieve net-zero emissions by 2050, covering Scope 1 and Scope 2 emissions.